Evidence map›Paper›PMID 35231996›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].

F C Kong, M Yu, Y L Zhou, S X Wang, F Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

F C KongCenter of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
M YuCenter of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Y L ZhouCenter of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
S X WangCenter of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
F LiCenter of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ImmunoconjugatesLymphoma, Large B-Cell, DiffuseAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideHumansRituximabAntibodies, MonoclonalBendamustine HydrochlorideImmunoconjugatespolatuzumab vedotinRituximab

Identifiers

PMID35231996
PMCPMC8980657
OpenAlexW4214935058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.